Neurofibromatoses is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Neurofibromatoses have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Neurofibromatoses compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neurofibromatoses overview
Neurofibromatosis (NF) is a term for a group of genetic disorders that cause benign tumors to grow on nerve tissue. There are three types of NF: NF1, NF2, and schwannomatosis. Each type has different signs and symptoms, such as skin spots, freckles, bumps, hearing loss, vision loss, pain, and bone deformities. NF is caused by mutations in certain genes that regulate nerve cell growth and division. NF can be inherited from a parent or occur spontaneously during early development. NF affects the nervous system, including the brain, spinal cord, and peripheral nerves. NF has no cure, but treatments can help manage the symptoms and complications. Surgery, radiation therapy, chemotherapy, and medication are some of the options available. NF is one of the most common genetic diseases in the US, affecting about 1 in 3,000 people.
For a complete picture of PTSR and LoA scores for drugs in Neurofibromatoses, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
